

**From pharmacogenetics to personalized cancer therapy**  
CRO-Aviano, December 14<sup>th</sup> 2009

**Registration : 8.30-9.00**

**Welcome: 9.00-9.15**

**Session 1: 9.15-11.00**

**Pharmacogenetics & Public Health**

**Chairpersons:**

Mark J Ratain - University of Chicago Medical Hospitals

Carlo Tomino - AIFA, Ministero della Salute

9.15-10.05

Mark J Ratain - University of Chicago Medical Hospitals

Pharmacogenomics: challenges and opportunities

10.05-10.25

Giuseppe Novelli - Univ. Di Roma Tor Vergata e PGWP EMEA London

The FDA and the EMEA Guidance for Industry and regulatory needs

10.25-10.45

Achille Caputi - Università degli Studi di Messina

Economic consequences of ADRs and potential impact of pharmacogenomics

**Coffee break: 10.45 - 11.00**

**Session 2: 11.00-13.30**

**Individualizing cancer therapy**

**Chairpersons:**

Tullio Giraldi – Università degli Studi di Trieste

Giuseppe Toffoli – Centro di Riferimento Oncologico, Aviano

11.00-11.20

Federico Innocenti - University of Chicago Medical Hospitals

Application of genome-wide technologies to identify novel candidate genes of treatment outcome

11.20-11.40

Giuseppe Toffoli – Centro di Riferimento Oncologico, Aviano

Pharmacogenetics for individualizing dosing: clinical utility.

11.40-12.00

Giulio Vittorio Scagliotti - Università di Torino  
Pharmacogenetics a prognostic and predictive marker

12.00-12.20

Antonella Pirazzoli - GlaxoSmithKline Spa - Pharmaceuticals  
Pharmacogenetics and future drug development and delivery

12.20-12.40

Michael Lahn – Ely Lilly

The Pharmacogenomic Relevance of Targeting Survivin In Cancer Patients: Lessons from a First in Human Dose (FHD) Study of the Survivin Antisense Oligonucleotide

12.40-13.00

Martin Potgeter – Qiagen

From bench to bedside: how new tools for pharmacogenetics/genomics improve clinical diagnosis

### **13.00-13.30 Round Table**

(AIOM, SIF, AIFA)

### **Lunch 13.30-14-30**

Session 3: 14.30-15.50

### **Integration of Pharmacogenomics in the Clinical practice 1**

#### Chairpersons

Carlo Riccardi – Università degli Studi di Perugia

Giulio Vittorio Scagliotti - Università di Torino

14.30-14.50

Alan Barge- Astra Zeneca :

EGFR pharmacogenomics and gefitinib clinical development

14.30-14.50

Federico Cappuzzo - Istituto Clinico Humanitas

Pharmacogenomic markers of response to EGFR and Kras

14.50-15.10

Alfredo Budillon – Istituto Pascale, Napoli

Pharmacogenetics/omics of anti-angiogenetic drugs

15.10-15.30

Enrico Mini – Università degli Studi di Firenze

Pharmacogenetics of fluoropyrimidines and anti-folate therapy

15.30-15.50

Erika Cecchin – Centro di Riferimento Oncologico, Aviano  
Genetic profiles of radiotherapy individualization

**Coffee break: 15.50 – 16.00**

Session 4: 16.00-17.20

**Integration of Pharmacogenomics in the Clinical practice 2**

Chairpersons

Fabio Puglisi – AIOM Friuli Venezia Giulia

Giampiero Fasola - Azienda Ospedaliera Santa Maria degli Angeli, Udine

16.0-16.20

to be defined

Genomics profiles for breast cancer treatment tailoring

16.20-16.40

Carmine Pinto - Policlinico Sant'Orsola –Malpighi

The Italian Project for the detection of KRAS-mutations in advanced colorectal cancer

16.40-17.00

Silvana Canevari – Istituto Nazionale Tumori Milano

Genomics profiles for ovarian Cancer treatment tailoring

17.00-17.20

Roberta Bertorelle – Istituto Oncologico Veneto

The role of pharmacogenetic profiling in the GIST treatment

## **AFFILIATIONS**

Alan Barge

VP Clinical Oncology

AstraZeneca U.K.

Alfredo Budillon

Director of Experimental Pharmacology Unit

Fondazione G. Pascale -Istituto Nazionale Tumori- Napoli

Roberta Bertorelle

Oncological Molecular Diagnostic Immunology

Istituto Oncologico Veneto

Padova

Silvana Canevari  
Head, Unit of Molecular Therapies  
Experimental Oncology Department  
Istituto Nazionale dei Tumori  
Milan

Achille Patrizio Caputi  
President of Italian Society of Pharmacology (SIF)  
Director of Clinical and Experimental Department of Medicine and Pharmacology  
University of Messina

Federico Cappuzzo  
Medical Oncology  
Istituto Clinico Humanitas  
Milan

Erika Cecchin  
Experimental and Clinical Pharmacology  
CRO- National Cancer Institute  
Aviano (PN)

Giampiero Fasola  
Director Medical Oncology  
Azienda Ospedaliera Santa Maria degli Angeli, Udine

Tullio Girdali  
Professor of Pharmacology  
Faculty of Medicine  
University of Trieste

Federico Innocenti  
Section of Hematology / Oncology Assistant Professor of Medicine  
Department of Medicine, Cancer Research Center,  
Committee on Pharmacology and Pharmacogenomics,  
The University of Chicago, Chicago, IL

Michael Lahn  
Medical advisor, Program Phase Oncology  
Lilly GmbH  
Bad Homburg, Germany

Enrico Mini  
Department of preclinical & clinical pharmacology  
Operative unit of pharmacology and clinical chemotherapy service  
University of Florence

Giuseppe Novelli  
Director of Medical Genetics Laboratory  
Tor Vergata University Rome  
PGWP EMEA London

Carmine Pinto  
Director of Medical oncology  
Azienda Ospedaliera University  
Trieste

Antonella Pirazzoli  
Director of Pharmacogenetics and Clinic Genetics  
GlaxoSmithKline Spa – Pharmaceuticals - Verona

Martin Potgeter  
Director Corporate Business Development  
QIAGEN GmbH  
Hilden, Germany

Fabio Puglisi  
Clinical Oncology- Breast Unit  
University of Udine

Mark J Ratain  
Leon O. Jacobson Professor of Medicine  
Chairman, Committee on Clinical Pharmacology and Pharmacogenomics  
Associate Director for Clinical Sciences, Cancer Research Center  
The University of Chicago, Chicago, IL

Carlo Riccardi  
Elect President of Italian Society of Pharmacology  
Professor of Pharmacology - Faculty of Medicine  
University of Perugia

Giulio Vittorio Scagliotti  
Faculty of Medicine San Luigi Gonzaga-University of Turin  
Director of Department of Lung Oncology  
Azienda Ospedaliera S. Luigi – Orbassano (TO)

Carlo Tomino  
Head of Clinical Trial  
Italian Medicines Agency  
Rome

Giuseppe Toffoli  
Director Experimental and Clinical Pharmacology Unit

CRO- National Cancer Institute  
Aviano (PN)

**Presidente del convegno:**

Giuseppe Toffoli

**Comitato scientifico o comitato organizzatore:**

Giuseppe Toffoli (CRO-Aviano)  
Tullio Girdali (SIF- Friuli Venezia Giulia)  
Federico Innocenti (The University of Chicago)

**Segreteria scientifica:**

Erika Cecchin

Altri?

SOC Farmacologia Sperimentale e Clinica  
Centro di Riferimento Oncologico  
Sede: via F. Gallini, 2 - 33081 Aviano (PN)  
tel: 0434-659667 - fax: 0434-659659  
e-mail: ececchin@cro.it

**Segreteria ECM:**

Servizio Formazione—Direzione Sanitaria  
Katya Da Frè  
Sede: via F. Gallini, 2 - 33081 Aviano (PN)  
tel: 0434 - 659830/508 - fax: 0434 - 659864  
e-mail: kdafre@cro.it

**Segreteria Organizzativa:**

The office srl  
Via San Nicolò, 14 - 34121 Trieste  
tel: 040-368343 – fax: 040-368808  
e-mail: cancertherapy09@theoffice.it  
sito web: www.theoffice.it